Amanote Research
Register
Sign In
Monoacyl Lipopeptide Agonist of Toll-Like Receptor 2 (TLR2) as a Vaccine Adjuvant
Science-Business eXchange
doi 10.1038/scibx.2013.773
Full Text
Open PDF
Abstract
Available in
full text
Date
August 1, 2013
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Toll-Like Receptor 2 (TLR2)
Science-Business eXchange
Intratumoural Injection of the Toll-Like Receptor-2/6 Agonist ‘Macrophage-Activating Lipopeptide-2’ in Patients With Pancreatic Carcinoma: A Phase I/Ii Trial
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Expression of Toll-Like Receptor 2 (TLR2) in Porcine Leukocyte Subsets and Tissues
Veterinary Research
Veterinary
Modulation of Toll-Like Receptor 2 (TLR2) and TLR4 Responses by Aspergillus Fumigatus
Infection and Immunity
Parasitology
Infectious Diseases
Immunology
Microbiology
OC33 Altered Toll Like Receptor 2 (TLR2) Signalling in Children With Down Syndrome
Adjuvant for Vaccine Immunotherapy of Cancer - Focusing on Toll-Like Receptor 2 and 3 Agonists for Safely Enhancing Antitumor Immunity
Cancer Science
Cancer Research
Medicine
Oncology
Toll Like-Receptor Agonist Pam3Cys Modulates the Immunogenicity of Liposomes Containing the Tuberculosis Vaccine Candidate H56
Medical Microbiology and Immunology
Medicine
Allergy
Immunology
Microbiology
A Critical Role of Toll-Like Receptor 2 (TLR2) and Its’ in Vivo Ligands in Radio-Resistance
Scientific Reports
Multidisciplinary
Synthetic Toll Like Receptor-4 (TLR-4) Agonist Peptides as a Novel Class of Adjuvants
PLoS ONE
Multidisciplinary
